Adage Capital Partners
SABS icon

Adage Capital Partners’s SAB Biotherapeutics SABS Stock Holding History

Adage Capital Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13M Buy
+3,405,553
New +$13.6M 0.02% 621

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SSC
Spruce Street Capital New York $416M AUM

Adage Capital Partners's SABS Position: Q1 2026 in Review

Adage Capital Partners opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 3,405,553 shares worth $13M. The stake represents 0.02% of the portfolio and ranks #621 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Adage Capital Partners held 3,405,553 shares of SAB Biotherapeutics worth $13M as of Q1 2026.
  • SAB Biotherapeutics was a new Adage Capital Partners position in Q1 2026.
  • SAB Biotherapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #621 holding.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.